ABSTRACT
Home oxygen therapy (HOT) is an important treatment for patients with chronic respiratory diseases. Recently, telemonitoring of HOT has been become available. In the present study, we examined whether telemonitoring of HOT could improve health-related quality of life (HRQOL). Twelve patients receiving HOT participated in this study. The oxygen flow rates, use of the oxygen concentrator, and the values of percutaneous arterial oxygen saturation measured by each patient with a pulse oximeter were checked using a telemonitoring system for a period of one month. Interventions based on the results obtained were carried out in order to optimize oxygen use in this patient cohort. We evaluated the results of the SF-36 questionnaire before the initiation of telemonitoring and at 3 months after completion of the study. We identified significant improvements in SF-36 sub-scores after completion of this intervention. We conclude that telemonitoring may be a useful method to improve HRQOL.
Keywords: arterial blood oxygen saturation, chronic respiratory failure, home oxygen therapy, pulse oximetry, quality of life
Home oxygen therapy (HOT) in patients with chronic respiratory failure is an important medical treatment that improves both the quality of life (QOL) and prognosis by providing long-term oxygen therapy at home.1, 2 Recent studies revealed that continuous oxygen inhalation for patients with chronic obstructive pulmonary disease (COPD) with chronic respiratory failure was economically more cost effective3 and was associated with a substantially better prognosis4 than oxygen therapy provided at night only. However, some patients do not take in sufficient oxygen while at home; the frequency and degree of hypoxia in patients with HOT remains unclear. Recently, a means of telemonitoring patients on HOT has been developed which will permit health care providers to monitor the use of oxygen concentrator and to review percutaneous arterial blood oxygen saturation as measured by pulse oximetry (SpO2). In this preliminary study, we examined the use of telemonitoring of HOT to determine whether this intervention resulted in improved health-related quality of life (HRQOL) in these patients.
SUBJECTS AND METHODS
Patients
Twelve patients (nine males and three females; 76.0 ± 9.8 years) receiving HOT for more than one year were recruited to participate in this study. Underlying diagnoses included: COPD (n = 5), sequelae of tuberculosis (n = 3), interstitial pneumonia (n = 2), bronchiectasis (n = 1), and scoliosis (n = 1). No patients were hospitalized during the study. The study was approved by Tottori University and the Hitachi Memorial Hospital ethical board (approval number 1636 and 17A006). All participants provided written informed consent.
Telemonitoring
Telemonitoring is a relatively new medical tool that has emerged from recent developments in information and communication technology. These devices are connected via standard mobile-based internet and the operating status and biological information are sent automatically and saved to a cloud server in a time series database. The physician can access and analyze these data at any time using his or her computer. In this study, we measured oxygen flow, use of the oxygen concentrator (FH-100/5L, Fukuda Denshi, Tokyo), and values of SpO2 and pulse rate via a pulse oximeter (Anypal, Fukuda Denshi). Data collected over a 1-month period were monitored at least every week by a physician using a dedicated telemonitoring system (Fukuda Home Management System, Fukuda Denshi). Interventions designed to improve respiratory parameters were carried out intermittently based on the results obtained.
Health-related QOL
The Medical Outcome Study 36-Item Short Form Health Survey (SF-36) questionnaire is a validated tool used to measure HRQOL. In the SF-36, one item is designed to assess perceived change in health status, and each of the remaining 35 items contributes to the score on one of eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). Scores on these eight scales were used to compute a summary index of physical health and a summary index of mental health.5, 6 We examined each study participant using the SF-36 questionnaire before telemonitoring of HOT and again 3 months later.
Statistical analyses
The values are presented as the median. We used Wilcoxon matched-pairs signed rank test to determine significant differences in SF-36 scores determined before and after telemonitoring of HOT (StatFlex, ViewFlex, Tokyo, Japan). Differences were considered to be statistically significant at P < 0.05.
RESULTS
Among the 12 HOT patients in our study, four required continuous oxygen therapy. We found that four of the patients required more inspired oxygen at rest as hypoxia was recognized by the values of self-measured SpO2 provided. Similarly, we found that five patients needed more oxygen during exercise. Appropriate interventions were made in each case. Particularly, the median time of oxygen inhalation was increased from 12.7 to 21.7 hours after appropriate interventions. Figure 1 presents the median scores of SF-36 questionnaire before telemonitoring began and scores from the same patients at 3 months later. Scores that evaluate VT and MH underwent significant improvement after the telemonitoring period (P < 0.04 and P < 0.02, respectively).
DISCUSSION
We were able to respond acutely to the need to adjust oxygen flow among the patients participating in our telemonitoring study. Appropriate interventions, including increasing inhalation time and/or altering the flow rate, were associated with improved scores on the SF-36 questionnaire.
The efficacy of telemonitoring of patients receiving HOT remains unclear. Segrelles Calvo and colleagues7 reported that telemonitoring of blood pressure, SpO2, pulse rate and peak flow from the patients with severe COPD receiving HOT significantly reduced the number of emergency room visits, number of hospitalizations and length of hospital stay (PROMETE study). As a part of this study, the patients were advised to visit a hospital when telemonitoring identified a possible exacerbation of COPD. Telemonitoring that includes SpO2 in association with physical activity might contribute to a more precise and appropriate understanding of oxygen needs8 and home-based health care providers capable of telemonitoring patients with COPD reported effective improvements in HRQOL.9 By contrast, Ancochea and colleagues10 reported that remote patient management using telemonitoring of blood pressure, SpO2, pulse rate, respiratory rate and spirometry from severe COPD patients receiving HOT did not result in reductions in COPD-related emergency room visits or hospital admissions. Since the patients receiving HOT are generally those with severe disease, it may be important to focus on the selection of suitable patients who can adapt to and function with telemonitoring. In this study, we found that the telemonitoring of HOT resulted in significant improvement of several of the sub-scores within the SF-36. As such, improvements in HRQOL may be directly related to this intervention, although other factors preclude a definitive conclusion on this subject at this time. This preliminary study is associated with several limitations, most notably small sample size, and we did not consider the control group that did not use telemonitoring of HOT. Further study will be needed to clarify the usefulness of telemonitoring of HOT and the resulting impact on HRQOL.
Acknowledgments
Acknowledgments: This work was supported by JSPS KAKENHI Grant Number 17K12454.
Footnotes
The authors declare no conflicts of interest.
REFERENCES
- 1.Miyamoto K,Aida A,Nishimura M,Aiba M,Kira S,Kawakami Y; The Respiratory Failure Research Group in Japan. Gender effect on prognosis of patients receiving long-term home oxygen therapy. Am J Respir Crit Care Med. 1995;152:972-6. 10.1164/ajrccm.152.3.7663812 [DOI] [PubMed] [Google Scholar]
- 2.Burioka N,Nakamoto S,Amisaki T,Horie T,Shimizu E. A modified method for examining the walking pattern and pace of COPD Patients in a 6-min walk test before and after the inhalation of procaterol. Intern Med. 2017;56:1949-55. 10.2169/internalmedicine.56.7961 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Oba Y. Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease. Am J Manag Care. 2009;15:97-104. [PubMed] [Google Scholar]
- 4.Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391-8. 10.7326/0003-4819-93-3-391 [DOI] [PubMed] [Google Scholar]
- 5.Fukuhara S,Bito S,Green J,Hsiao A,Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037-44. 10.1016/S0895-4356(98)00095-X [DOI] [PubMed] [Google Scholar]
- 6.Fukuhara S,Ware JE Jr,Kosinski M,Wada S,Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998;51:1045-53. 10.1016/S0895-4356(98)00096-1 [DOI] [PubMed] [Google Scholar]
- 7.Segrelles Calvo G,Gómez-Suárez C,Soriano JB,Zamora E,Gónzalez-Gamarra A,González-Béjar M,et al. . A home telehealth program for patients with severe COPD: the PROMETE study. Respir Med. 2014;108:453-62. 10.1016/j.rmed.2013.12.003 [DOI] [PubMed] [Google Scholar]
- 8.Faria I,Gaspar C,Zamith M,Matias I,César das Neves R,Rodrigues F,et al. . TELEMOLD project: oximetry and exercise telemonitoring to improve long-term oxygen therapy. Telemed J E Health. 2014;20:626-32. 10.1089/tmj.2013.0248 [DOI] [PubMed] [Google Scholar]
- 9.McDowell JE,McClean S,FitzGibbon F,Tate S. A randomised clinical trial of the effectiveness of home-based health care with telemonitoring in patients with COPD. J Telemed Telecare. 2015;21:80-7. 10.1177/1357633X14566575 [DOI] [PubMed] [Google Scholar]
- 10.Ancochea J,García-Río F,Vázquez-Espinosa E,Hernando-Sanz A,López-Yepes L,Galera-Martínez R,et al. . Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Eur Respir J. 2018;51:1800354. 10.1183/13993003.00354-2018 [DOI] [PubMed] [Google Scholar]